← Natera overview
Natera IncNTRA

Why is Natera (NTRA) moving?

Q3 2026
▲3▼1

Natera's Signatera Gains EU Access, Record Revenue, Analyst Upgrades

  • EU IVDR Class C Certification Signatera received EU IVDR Class C certification, ensuring Natera can keep selling the test in Europe beyond 2028. This removes a major regulatory risk and secures a key market for future growth.

    New regulatory approval that secures European market access, a key positive for future revenue.

  • Record Q2 Revenue and Raised Guidance Natera reported record Q2 revenue of $753 million, up 38% from a year ago, and raised its full-year 2026 revenue guidance to $2.85–2.91 billion. Gross margins improved to 65%, showing better profitability.

    Strong financial results and increased outlook directly boost investor confidence and stock price.

  • Signatera Expansion and Analyst Upgrades Signatera expanded into new clinical trials (Angiex, AFT-70 NAVIGATE) and Natera presented the largest lung cancer MRD dataset, supporting adoption. Analysts raised fair value to $344.33, with UBS initiating at Buy and a $435 target.

    New trial partnerships and analyst upgrades signal growing adoption and future revenue potential.

  • Valuation and Insider Selling Risks Despite strong momentum, Natera's stock trades at 16 times sales, insiders are selling shares, and the company remains unprofitable. These factors could limit further upside and add volatility.

    High valuation and insider selling are real counterweights that could cap stock gains.

August 2026
▲4

Natera's Signatera Momentum Builds as Analysts Raise Targets

  • Signatera Expands into New Clinical Trials Natera's Signatera test is being used in two new clinical trials: Angiex's Phase 1 solid tumor study and the AFT-70 NAVIGATE Phase III breast cancer trial. More trial use builds evidence and familiarity, which can lead to more doctors ordering the test and higher future revenue.

    New trial partnerships directly expand Signatera's clinical footprint and support future demand.

  • Largest Lung Cancer MRD Dataset Reinforces Signatera Natera presented the largest lung cancer MRD dataset at a major conference, showing Signatera strongly predicts recurrence and survival. Strong clinical evidence supports broader adoption and payer coverage, which can drive test volume and revenue growth.

    New clinical data strengthens the case for Signatera in lung cancer, a key growth area.

  • Analysts Raise Fair Value on Signatera Execution Analysts lifted Natera's fair value to $344.33 from $282.14, citing Signatera execution and updated forecasts. Multiple firms raised targets, with UBS starting coverage at Buy and a $435 target. Higher targets can attract investors and support the stock price.

    Analyst upgrades and higher price targets directly influence investor sentiment and valuation.

  • Strong Test Volume and Margin Improvement Natera processed over one million tests in a quarter for the first time, with revenue up 38.8%. Margins and free cash flow improved, showing the business is scaling profitably. This operational strength supports the stock's valuation and growth story.

    Record test volume and improving financials demonstrate fundamental business momentum.

Latest
▲4

Natera's Signatera Momentum Builds as Analysts Raise Targets

  • Signatera Expands into New Clinical Trials Natera's Signatera test is being used in two new clinical trials: Angiex's Phase 1 solid tumor study and the AFT-70 NAVIGATE Phase III breast cancer trial. More trial use builds evidence and familiarity, which can lead to more doctors ordering the test and higher future revenue.

    New trial partnerships directly expand Signatera's clinical footprint and support future demand.

  • Largest Lung Cancer MRD Dataset Reinforces Signatera Natera presented the largest lung cancer MRD dataset at a major conference, showing Signatera strongly predicts recurrence and survival. Strong clinical evidence supports broader adoption and payer coverage, which can drive test volume and revenue growth.

    New clinical data strengthens the case for Signatera in lung cancer, a key growth area.

  • Analysts Raise Fair Value on Signatera Execution Analysts lifted Natera's fair value to $344.33 from $282.14, citing Signatera execution and updated forecasts. Multiple firms raised targets, with UBS starting coverage at Buy and a $435 target. Higher targets can attract investors and support the stock price.

    Analyst upgrades and higher price targets directly influence investor sentiment and valuation.

  • Strong Test Volume and Margin Improvement Natera processed over one million tests in a quarter for the first time, with revenue up 38.8%. Margins and free cash flow improved, showing the business is scaling profitably. This operational strength supports the stock's valuation and growth story.

    Record test volume and improving financials demonstrate fundamental business momentum.

July 2026
▲3

Natera's Record Q2, Raised Guidance, and EU Certification Drive Momentum

  • EU IVDR Class C Certification for Signatera Natera's Signatera test secured EU Class C certification under IVDR, ensuring continued market access in Europe beyond 2028. This strengthens regulatory standing and supports clinical trial adoption, which investors see as key to sustaining revenue growth.

    This is a new regulatory milestone that directly supports Signatera's European market position and future revenue.

  • Record Q2 Revenue and Raised 2026 Guidance Natera reported Q2 revenue of $753 million, up 38% year-over-year, with record test volumes and raised full-year guidance to $2.85–$2.91 billion. Gross margin improved to 65%, and Signatera's average selling price rose, signaling strong pricing power and operational scaling.

    This is the core financial update that shows accelerating growth and improved profitability, directly driving the stock's recent rally.

  • New Trial Collaboration for Latitude Test Natera announced a collaboration to use its Latitude MRD test in a Phase 1 trial for Kupando's immunotherapy candidate. This expands clinical use and validates the test's potential in new cancer indications, supporting long-term demand.

    This is a new business development that broadens the clinical application of Natera's products.

  • Druckenmiller's Continued Confidence vs. Valuation and Insider Selling Stanley Druckenmiller's family office holds Natera as its top position, worth about $865 million, reflecting strong institutional confidence. However, the stock trades at 16 times sales, insiders are selling, and the company remains unprofitable, which could cap upside.

    This highlights the key counterweight: strong investor backing but high valuation and profitability concerns.

▲3

Natera's Record Q2, Raised Guidance, and EU Certification Drive Momentum

  • EU IVDR Class C Certification for Signatera Natera's Signatera test secured EU Class C certification under IVDR, ensuring continued market access in Europe beyond 2028. This strengthens regulatory standing and supports clinical trial adoption, which investors see as key to sustaining revenue growth.

    This is a new regulatory milestone that directly supports Signatera's European market position and future revenue.

  • Record Q2 Revenue and Raised 2026 Guidance Natera reported Q2 revenue of $753 million, up 38% year-over-year, with record test volumes and raised full-year guidance to $2.85–$2.91 billion. Gross margin improved to 65%, and Signatera's average selling price rose, signaling strong pricing power and operational scaling.

    This is the core financial update that shows accelerating growth and improved profitability, directly driving the stock's recent rally.

  • New Trial Collaboration for Latitude Test Natera announced a collaboration to use its Latitude MRD test in a Phase 1 trial for Kupando's immunotherapy candidate. This expands clinical use and validates the test's potential in new cancer indications, supporting long-term demand.

    This is a new business development that broadens the clinical application of Natera's products.

  • Druckenmiller's Continued Confidence vs. Valuation and Insider Selling Stanley Druckenmiller's family office holds Natera as its top position, worth about $865 million, reflecting strong institutional confidence. However, the stock trades at 16 times sales, insiders are selling, and the company remains unprofitable, which could cap upside.

    This highlights the key counterweight: strong investor backing but high valuation and profitability concerns.

Q2 2026
▲3

Natera's Signatera Wins Guideline, Japan Approval; Trial Deals Expand Use

  • NCCN guideline recommends Signatera for bladder cancer NCCN, which sets US cancer treatment standards, now recommends Signatera for muscle-invasive bladder cancer. This should drive more doctors to order the test, boosting revenue. It's the first such recommendation for this cancer type.

    This is a major new regulatory/guideline endorsement that expands the market for Natera's flagship test.

  • Japan approves Signatera for colorectal cancer Japan's drug regulator approved Signatera for colorectal cancer, the first MRD test approved there. Natera plans to launch by end of 2026. Japan diagnoses over 150,000 colorectal cancer cases yearly, a large new market.

    This opens a major new geographic market for Signatera, directly increasing potential revenue.

  • New trial partnerships expand Signatera and Prospera use Natera signed deals to use Signatera in CytoDyn's colorectal cancer trial and Aveta's head and neck cancer trial, and Prospera in Eledon's kidney transplant trial. These generate revenue and build evidence for broader adoption.

    These partnerships show growing adoption of Natera's tests in drug development, supporting future revenue and clinical credibility.

June 2026
▲3

Natera's Signatera Wins Guideline, Japan Approval; Trial Deals Expand Use

  • NCCN guideline recommends Signatera for bladder cancer NCCN, which sets US cancer treatment standards, now recommends Signatera for muscle-invasive bladder cancer. This should drive more doctors to order the test, boosting revenue. It's the first such recommendation for this cancer type.

    This is a major new regulatory/guideline endorsement that expands the market for Natera's flagship test.

  • Japan approves Signatera for colorectal cancer Japan's drug regulator approved Signatera for colorectal cancer, the first MRD test approved there. Natera plans to launch by end of 2026. Japan diagnoses over 150,000 colorectal cancer cases yearly, a large new market.

    This opens a major new geographic market for Signatera, directly increasing potential revenue.

  • New trial partnerships expand Signatera and Prospera use Natera signed deals to use Signatera in CytoDyn's colorectal cancer trial and Aveta's head and neck cancer trial, and Prospera in Eledon's kidney transplant trial. These generate revenue and build evidence for broader adoption.

    These partnerships show growing adoption of Natera's tests in drug development, supporting future revenue and clinical credibility.

▲3

Natera's Signatera Wins Guideline, Japan Approval; Trial Deals Expand Use

  • NCCN guideline recommends Signatera for bladder cancer NCCN, which sets US cancer treatment standards, now recommends Signatera for muscle-invasive bladder cancer. This should drive more doctors to order the test, boosting revenue. It's the first such recommendation for this cancer type.

    This is a major new regulatory/guideline endorsement that expands the market for Natera's flagship test.

  • Japan approves Signatera for colorectal cancer Japan's drug regulator approved Signatera for colorectal cancer, the first MRD test approved there. Natera plans to launch by end of 2026. Japan diagnoses over 150,000 colorectal cancer cases yearly, a large new market.

    This opens a major new geographic market for Signatera, directly increasing potential revenue.

  • New trial partnerships expand Signatera and Prospera use Natera signed deals to use Signatera in CytoDyn's colorectal cancer trial and Aveta's head and neck cancer trial, and Prospera in Eledon's kidney transplant trial. These generate revenue and build evidence for broader adoption.

    These partnerships show growing adoption of Natera's tests in drug development, supporting future revenue and clinical credibility.